Supernus Pharmaceuticals (SUPN) Cash from Financing Activities (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Cash from Financing Activities data on file, last reported at $9.1 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 142.6% year-over-year to $9.1 million in Q1 2026; TTM through Mar 2026 was $39.6 million, a 467.89% increase from a year earlier, with the FY2025 full-year figure at $9.1 million, down 25.12% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $9.1 million, up from $8.5 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for SUPN reached as high as $80.2 million in Q1 2023 and fell as low as -$478.9 million in Q2 2023.
• Historically, Cash from Financing Activities has averaged -$22.2 million across 5 years, with a median of $2.3 million in 2022.
• Across the five-year window, Cash from Financing Activities plunged 21169.78% in 2023 and surged 1436.96% in 2024, its largest moves.
• Year by year, Cash from Financing Activities stood at $2.8 million in 2022, then sank by 61.4% to $1.1 million in 2023, then surged by 439.38% to $5.9 million in 2024, then surged by 44.75% to $8.5 million in 2025, then rose by 6.91% to $9.1 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $9.1 million in Q1 2026, $8.5 million in Q4 2025, and $21.1 million in Q3 2025.